Big Bite: Biden demands insurance companies cover medical "gender-affirming care" after the FDA added a warning to puberty blockers
Big bite | A detailed dive into big news
On July 1, the Food and Drug Administration (FDA) added a warning to multiple gonadotropin-releasing hormone (GnRH) agonists, drugs often used as puberty blockers in gender-confused youth.
The FDA identified six cases where there was a “plausible” link between GnRH agonists and a condition called pseudotumor cerebri, which is caused by elevated fluid pressure in the brain.
According to the FDA, all six cases were identified in biologically female children between the ages of 5 and 12; five of the six were being treated for early puberty, and the sixth was undergoing “transgender care.”
According to the Daily Wire, symptoms included specifically, “visual disturbances, headaches, and vomiting.” In addition, “Other effects GnRH agonists caused were an increase in blood pressure, brain swelling, and abducens neuropathy.”
On July 18, a clip of Biden's Assistant Secretary for Health Rachel Levine speaking about youth gender affirmation treatment went viral: In the clip, Levine said, “We really want to ... affirm and to support and empower these youths, not to limit their participation in activities ... and even limit their ability to get gender affirmation treatment in their state."
Less than one month after the FDA issued the warning on puberty blockers, the Biden administration early last week announced a new plan to modify the Affordable Care Act. The plan would remove safeguarding measures that currently prevent children from having easy access to sex change treatments, sorry or, in progressive speak, "gender-affirmation" care.
These treatments include puberty blockers, cross-sex hormones, and surgeries. The proposal applies to Obamacare health plans, Medicaid, and Medicare.
Puberty Blockers are Reversible?, It’s Meseidy